Compare TORO & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TORO | ALXO |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.5M | 205.9M |
| IPO Year | 2022 | 2020 |
| Metric | TORO | ALXO |
|---|---|---|
| Price | $6.06 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 25.0K | ★ 731.7K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.95 | $1.05 |
| 52 Week High | $8.50 | $2.66 |
| Indicator | TORO | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 35.29 |
| Support Level | $4.87 | $1.56 |
| Resistance Level | $6.15 | $2.17 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 20.03 | 7.14 |
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.